miR-101 and EZH2 in Blood Vessel Formation
Author Information
Author(s): Smits Michiel, Mir Shahryar E., Nilsson R. Jonas A., van der Stoop Petra M., Niers Johanna M., Marquez Victor E., Cloos Jacqueline, Breakefield Xandra O., Krichevsky Anna M., Noske David P., Tannous Bakhos A., Würdinger Thomas
Primary Institution: VU University Medical Center, Amsterdam, The Netherlands
Hypothesis
The study investigates the role of miR-101 in regulating EZH2 and its impact on angiogenesis.
Conclusion
Inhibition of EZH2 can reduce blood vessel formation in glioblastomas, suggesting a potential therapeutic approach.
Supporting Evidence
- VEGF down-regulates miR-101, leading to increased EZH2 expression.
- Inhibition of EZH2 reduces tubule formation in endothelial cells.
- Systemic administration of DZNep reduces blood vessel formation in glioblastoma models.
- miR-101 directly targets EZH2, confirming its regulatory role.
Takeaway
This study shows that a tiny molecule called miR-101 helps control another molecule, EZH2, which is important for making new blood vessels. If we can stop EZH2, we might be able to help treat certain cancers.
Methodology
The study used in vitro experiments with primary endothelial cells and in vivo mouse models to assess the effects of miR-101 and EZH2 on angiogenesis.
Limitations
The study was conducted in an immune-compromised mouse model, which may not fully represent the human immune response.
Participant Demographics
The study involved human brain microvascular endothelial cells and glioblastoma samples from patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website